The pharmaceutical world is witnessing a significant shift in diabetes treatment with the arrival of GLP-1 transdermal devices. These systems offer a seemingly more user-friendly alternative to subcutaneous administrations of GLP-1 receptor agonists, reducing the requirement of daily needle pokes